Premium Rimegepant API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Rimegepant / Rimegepant Sulfate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

Indications: Acute and Preventive Treatment of Migraine Headaches

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Rimegepant distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Rimegepant is an orally bioavailable, small-molecule Active Pharmaceutical Ingredient (API). In the field of neurological pharmacology, it is classified within a novel group of medications known as "gepants," which function as highly selective calcitonin gene-related peptide (CGRP) receptor antagonists.

For pharmaceutical manufacturers expanding their central nervous system (CNS) portfolios, this API provides a critical mechanism for the management of severe migraine headaches. The pathophysiology of a migraine involves the release of CGRP, a potent neuropeptide that binds to receptors on cranial blood vessels and mast cells, triggering severe neurogenic inflammation, vasodilation, and the transmission of pain signals.

By competitively binding to and blocking the CGRP receptor, Rimegepant inhibits this inflammatory and vasodilatory cascade. Unlike legacy acute migraine treatments (such as triptans or ergotamines), Rimegepant neutralizes the migraine pathway without inducing active vasoconstriction. This unique pharmacological profile provides formulators with a distinct cardiovascular safety advantage. In commercial manufacturing, this active ingredient is most commonly formulated into an immediate-release 75 mg orally disintegrating tablet (ODT) or standard oral solid tablet.

Sourcing Rimegepant in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced neurological formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty CNS APIs for local commercial manufacturing frequently involves navigating extended international lead times, stringent customs bottlenecks, and highly complex regulatory compliance documentation. Sourcing Rimegepant Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether your facility requires a standard pilot batch or is scaling up a high-volume Rimegepant api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending, granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Rimegepant API (often supplied as Rimegepant Sulfate) distributed by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
• CAS Number: 1289023-67-1 (Free Base) / 1642783-82-1 (Sulfate Salt)
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C28H28F2N6O3 (Base)
• Molecular Weight: 534.56 g/mol (Base)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling, pre-formulation stability studies, and salt-form selection.

Manufacturing and Handling Guidelines for Formulators

While Rimegepant does not carry the severe occupational hazards of cytotoxic oncology drugs, it remains a pharmacologically active CNS compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow standard industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.